Theriva Biologics, Inc. Cash And Cash Equivalents At Carrying Value

• Theriva Biologics, Inc. showed an increase of +12.5% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
• This data is from Theriva Biologics, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
• XBRL data for this metric is available from 2011 to 2025 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q4 2009: $2.72 million | Q2 2010: $3.27 million | Q3 2010: $3.31 million | Q4 2010: $2.65 million | Q2 2011: $8.39 million | Q3 2011: $4.61 million | Q1 2013: $8.52 million | Q2 2013: $6.88 million | Q3 2013: $5.15 million | Q1 2014: $11.16 million | Q2 2014: $7.84 million | Q3 2014: $3.29 million | Q1 2015: $12.05 million | Q2 2015: $4.76 million | Q3 2015: $31.81 million | Q1 2016: $15.10 million | Q2 2016: $10.05 million | Q3 2016: $4.55 million | Q1 2017: $13.47 million | Q2 2017: $13.38 million | Q3 2017: $21.05 million | Q1 2018: $11.04 million | Q2 2018: $7.13 million | Q3 2018: $9.55 million | Q1 2019: $24.69 million | Q2 2019: $23.00 million | Q2 2019: $21.71 million | Q3 2019: $20.10 million | Q3 2019: $18.65 million | Q4 2019: $15.05 million | Q1 2020: $10.09 million | Q2 2020: $8.06 million | Q3 2020: $6.01 million | Q1 2021: $76.89 million | Q2 2021: $74.29 million | Q3 2021: $72.14 million | Q1 2022: $56.69 million | Q2 2022: $52.27 million | Q3 2022: $50.49 million | Q1 2023: $36.08 million | Q2 2023: $34.25 million | Q3 2023: $31.16 million | Q1 2024: $18.26 million | Q2 2024: $16.59 million | Q3 2024: $16.41 million | Q1 2025: $10.01 million | Q2 2025: $12.12 million | Q3 2025: $7.53 million.
• Over the full 18 years of available data (2011 to 2025), Theriva Biologics, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 95.5%.
• Historical annual values: Fiscal year 2025: $13.06 million | Fiscal year 2024: $11.61 million | Fiscal year 2023: $23.18 million | Fiscal year 2022: $41.79 million | Fiscal year 2022: $50.49 million | Fiscal year 2022: $52.27 million | Fiscal year 2021: $67.33 million | Fiscal year 2020: $6.23 million | Fiscal year 2019: $15.05 million | Fiscal year 2019: $26.00 million | Fiscal year 2018: $28.92 million | Fiscal year 2017: $17.12 million | Fiscal year 2016: $19.06 million | Fiscal year 2015: $20.82 million | Fiscal year 2014: $17.53 million | Fiscal year 2013: $14.63 million | Fiscal year 2012: $9.95 million | Fiscal year 2011: $6.68 million.
• Data sourced from SEC EDGAR public filings as of August 10, 2026.

Last verified: August 10, 2026